Published in final edited form as:

Mol Pharm. 2012 February 6; 9(2): 281–289. doi:10.1021/mp200376c.

Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice

Joseph S. Zakhari^{1,2,4,5}, Eric P. Zorrilla³, Bin Zhou^{1,2,4}, Alexander V. Mayorov^{1,2,4}, and Kim D. Janda^{1,2,4,5,*}

¹Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

²Department of Immunology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

³Department of Molecular Integrative Neurosciences, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

⁴The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

⁵The Worm Institute of Research and Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

Abstract

Ghrelin, an enteric peptide hormone linked to the pathophysiology of obesity has been a therapeutic target of great interest over the past decade. Many research efforts have focused on the antagonism of ghrelin's endogenous receptor GHSR1a, which is found along ascending vagal afferent fibers, as well as in the arcuate nucleus of the hypothalamus. Additionally, peptidic inhibitors against ghrelin *O*-acyltransferase, the enzyme responsible for the paracrine activation of ghrelin, have recently been studied. Our research has taken an alternative immunological approach, studying both active and passive vaccination as a means to sequester ghrelin in the periphery, with the original discovery in rat of decreased feed efficiency and adiposity, as well as increased metabolic activity. Using our previous hapten designs as a stepping-stone, three monoclonal antibodies (**JG2**, **JG3**, and **JG4**) were procured against ghrelin and tested *in vivo*. While mAb **JG4** had the highest affinity for ghrelin, it failed to attenuate the orexigenic effects of food deprivation on energy metabolism or food intake in mice. However, animals that were administered a combination of **JG3:JG4**, (termed a doublet), or **JG2:JG3:JG4**, (termed a triplet), demonstrated higher heat dispersion and rate of respiration (higher CO₂ emission and O₂ consumption) during a 24-hr fast refeed. Mice administered the triplet cocktail of **JG2:JG3:JG4** also demonstrated decreased food intake upon refeeding as compared to control animals. Recently, Lu and colleagues reported that a passive approach using a single, high affinity *N*-terminally directed monoclonal antibody did not abrogate the effects of endogenous ghrelin. Our current report corroborates this finding, yet, refutes that a monoclonal antibody approach cannot be efficacious. Rather, we find that a multiple monoclonal antibody (oligoclonal) approach can reproduce the underlying logic to previously reported efficacies using active vaccinations.

Keywords

ghrelin; monoclonal antibodies; passive vaccination; active vaccination; metabolism; food intake

*Corresponding author. Tel.: +1 858 784 2515; fax +1 858 784 2595. kdjanda@scripps.edu (K. D. Janda).

INTRODUCTION

Obesity, defined as a body mass index of 30 kg/m² or greater, is an increasingly prevalent global health concern that carries increased risk of morbidity and mortality.^{1, 2} Many hormones and regulatory pathways, both energy homeostatic and non-homeostatic, are involved in the pathophysiology of obesity, a complex, multifactorial medical issue.³ One hormone implicated in the control of food intake and perhaps in some forms of obesity is ghrelin (Ghr).⁴

Ghrelin, a 28 amino acid residue enteric peptide hormone, was discovered in 1999 by Kojima and others while seeking the endogenous ligand for the growth hormone secretagogue receptor, GHS-R1a. The enteric expression of Ghr, produced in the stomach by X/A oxyntic mucosal cells, correlates negatively with blood glucose levels, food intake levels, and leptin levels.⁴ Plasma Ghr levels rise preprandially and decline postprandially, consistent with the hypothesized role of Ghr in hunger and meal initiation.⁵ Patients with Prader-Willi syndrome, a chromosomal mutation disorder with obesity, show 4–5 fold elevations in circulating ghrelin as compared to obese controls; the elevated ghrelin levels are proposed to drive the voracious hyperphagia seen in children with this disorder.^{6, 7} Caloric restriction (e.g., dieting) or fasting also increase circulating ghrelin levels, a putative counter-regulatory mechanism that impedes maintenance of weight loss.⁸ Thus, ghrelin and the biochemical pathways it impacts are putative therapeutic targets for the control of appetite and/or body weight.⁵

Ghrelin also influences energy homeostasis by reducing energy expenditure. For example, Yasuda and colleagues demonstrated that centrally administered ghrelin decreases sympathetic nerve activity in rat brown adipose tissue (BAT), which contributes to energy expenditure and thermogenesis via uncoupling protein 1 (UCP1).⁹ Conversely, young ghrelin-null mutant mice showed increased whole-body energy expenditure.^{10, 11} Systemic administration of proghrelin, the ghrelin precursor, also reduced respiratory quotient in mice, indicating decreased utilization of lipid as a fuel substrate.¹²

The octanoylation of the serine-3 residue by ghrelin *O*-acyltransferase enzyme (GOAT) is required for the potent affinity and agonist activity of Ghr at GHS-R1a, a 7 trans-membrane domain receptor found primarily in the pituitary, hypothalamus, and hippocampus. Octanoylated Ghr binding to GHS-R1a leads to trimerization of the G-protein receptor and downstream coupling to the phosphoinositidase C-linked $G_{\alpha_9}/G_{\alpha_{11}}$ proteins, which in turn upregulate intracellular Ca^{2+} levels.¹³ GHS-R1a appears to be the primary target via which ghrelin induces growth hormone (GH) secretion and stimulates appetite,³ leading to increased caloric intake, body weight, and adiposity.¹⁴ Other molecular targets of Ghr have also been suggested¹⁵ (AMPK), and may play additional roles in the peptide's regulatory effects on metabolism and energy homeostasis. Acylated Ghr comprises only about 10% of the Ghr in circulation (~117 $\pm$ 37 fmol/mL),¹⁶ and *des*-acyl Ghr, while inactive at GHS-R1a, might be active at such molecular targets.¹⁵

Potent sites of central action for exogenous Ghr to induce food intake include the arcuate nucleus (ARC) of the hypothalamus¹⁶ and the caudal hindbrain in the vicinity of the 4th ventricle.¹⁷ However, peripheral Ghr can also signal the central nervous system (CNS) directly, via the afferent fibers of the ascending vagus nerve, the primary neuroanatomic linkage between the alimentary tract and the nucleus of the solitary tract in the hindbrain. Surgical deafferentation of the gastric vagus blocks the ability of peripheral Ghr administration to increase food intake without attenuating the orexigenic effects of central Ghr administration.¹⁸ Peripheral Ghr signals through the vagus nerve to the AZ noradrenergic cell groups of the nucleus tractus solitarius (NTS)¹⁹ leading to increased

expression of the anabolic molecules neuropeptide Y (NPY) and agouti-related protein (AgRP) in the ARC.²⁰ Thus, enteric Ghr might modulate energy homeostasis via both peripheral (vagus) and central (endocrine permeation of blood-brain barrier) sites of action. GOAT, which has been shown to be produced within the CNS in addition to the stomach,²¹ also may activate Ghr to act locally in paracrine or autocrine fashion.

In light of the reviewed findings, ghrelin and its receptor have been key targets for weight modulation therapies in the past.^{22, 23} For example, small molecule antagonists of GHS-R1a have been shown to reduce food intake and whole-body weight in part by increasing the oxidation of body fat stores.²² Using an approach to block endogenous ghrelin directly, Becskei and colleagues created an anti-ghrelin RNA-spiegelmer (NOX-B11-3) that blocks ghrelin induced c-Fos neuronal activation in the ARC.²⁴ Helmling and others previously used the same approach creating a RNA-spiegelmer that suppressed ghrelin-induced GH release in rats.²⁵

Using an immunopharmacotherapy approach, we and others have found that active immunization to generate a polyclonal response against ghrelin reduced weight gain and/or adiposity in multiple species.^{26–27, 28} For example, in male Wistar rats, we reported that two haptens against acylated ghrelin, including Ghr1 (residues 1–10) and Ghr3 (full length, residues 1–28), conjugated to keyhole limpet hemocyanin (KLH) led to decreased feed efficiency, relative adiposity, and body weight gain²⁶ in direct relation to the affinity of the anti-ghrelin polyclonal response. Vizcarra and colleagues detailed that in growing pigs, feed intake was decreased by more than 15% in actively immunized subjects, and that overall weight gain in treated pigs was 10% less than control animals.²⁷ Finally, we recently found in adult mice that active immunization against ghrelin reduced adiposity, curbed spontaneous/deprivation-induced food intake, and facilitated net weight loss after food deprivation and refeeding.²⁸ Our group further demonstrated that passive immunization with GHR-11E11, a catalytic antibody that can degrade the ester moiety on the serine-3 residue of octanoylated ghrelin, converting acyl ghrelin to “inactive” *des*-acyl ghrelin, (k_{cat}/K_M of $9 \text{ M}^{-1}\text{s}^{-1}$), induced a higher metabolic rate during fasting as compared to mice immunized with a control antibody.²⁹ Following our research leads, Lu and colleagues developed a high-affinity *N*-terminally directed monoclonal antibody (mAb) against acyl-ghrelin. Passive administration of this single mAb only blocked exogenous ghrelin-induced food intake; however, it failed to modulate spontaneous food intake or body weight gain in obese mice over a 4-week study.³⁰

The negative of findings of Lu and colleagues could potentially be interpreted in one of two broad ways. One interpretation might be that endogenous ghrelin does not play a pertinent, non-redundant role in energy homeostasis, a view based largely on observations that adult ghrelin-null mice show normal food intake, energy expenditure, and body weight when fed chow *ad libitum*.^{11, 31, 32} An alternative interpretation is that ghrelin does play an essential role, but that the passive immunization approach used by Lu and colleagues was insufficient to abrogate the peptide's function. Given the reported inability of passive immunization with a single, high-affinity mAb to alter energy homeostasis substantively³⁰ and the ability of active immunization, which generates a polyclonal response to modulate aspects of energy homeostasis in multiple species,^{26–28} we hypothesized that monoclonal (i.e., single epitope) targeting might be insufficient to abrogate ghrelin's action and that an oligoclonal (i.e., multiple epitope) approach might be crucial to previous findings seen with active immunization. Indeed, others have previously shown synergy between oligoclonal antibodies in neutralizing botulinum neurotoxin (BoNT), tetanus toxin, or HIV infection.^{33–36} Herein, we confirm Lu et al's finding that acute administration of a high-affinity, *N*-terminally directed mAb against ghrelin *per se* is insufficient to alter energy expenditure or food intake in mice. We demonstrate, however, that synergistic combinations

of pairs or triplets of anti-ghrelin mAbs increased energy expenditure and/or reduced refeeding in fasted mice, suggesting that oligoclonal (or polyclonal) immunosequestration of peripheral ghrelin is required to attenuate its biological action on energy homeostasis.

MATERIALS AND METHODS

Synthesis and Screening of Anti-Ghrelin Antibodies

All haptens were prepared on a 1.0 mmol scale using solid-phase peptide synthesis²⁶. The first hapten was comprised of the first 10 amino acids of ghrelin (*N*-terminus), with an additional cysteine residue appended at the *C*-terminus. The immunogenic carrier protein keyhole limpet hemocyanin (KLH) was conjugated to the 10-mer using a sulfosuccinimidyl-4-[*N*-maleimidomethyl]cyclohexane-1-carboxylate (SMCC) linker at the *C*-terminal cysteine. The antibody generated from this hapten was labeled **JG4 1C4**. Monoclonal antibody **JG3 8H11** was elicited against full-length ghrelin-KLH, but wherein the octanoylated ester was abbreviated to a butyryl ester due to insolubility issues. **JG2 7B4** monoclonal antibody was elicited against ghrelin amino acids 13–28-KLH. All the haptens and substrates were prepared as *C*-terminal amides. The subsequent monoclonal antibodies were purified from ascities using ion-exchange and protein G affinity chromatography.

Binding analysis by BIAcore

A BIAcore™ 3000 instrument (BIAcore, Uppsala, Sweden) was utilized to determine directly whether the mAbs interacted with full-length acyl-ghrelin and *des*-acyl ghrelin peptides or ghrelin fragments (Ghr 1–5 and 1–10, Peptides International, Inc.). Each tested mAb was immobilized onto a CM3 or CM5 chip using the NHS/EDC coupling method, as well as an in-line reference flow cell coupled with an unrelated mAb (**NIC-1 9D9**). All measurements were conducted in HEPES buffer (pH 7.6) containing 0.15M NaCl, 3 mM EDTA, and 0.005% surfactant P20 (HBS-EP) running buffer at 25 °C with a flow-rate of 30 µL/min. Acyl, *des*-acyl ghrelin, or ghrelin fragments, were prepared in running buffer at various concentrations ranging from 1 nM to 50 µM and then injected over the mAb-immobilized flow cells. The binding response observed 2.5 minutes after the end-of-injection was used to define the binding capacity for each mAb against different concentrations of ghrelin peptides. A response ten times higher than the standard deviation of buffer injections was considered “positive” binding.

Kinetic analysis by BIAcore

To determine the kinetic constants of each defined mAb against acyl-ghrelin or ghrelin fragments, mAbs immobilized onto a CM3 chip were targeted at 3000 RU (for acyl-ghrelin), or a CM5 chip at 6,000 RU (for Ghr 1–10) and 10,000 RU (for Ghr 1–5) respectively, in order to acquire similar $R_{\max}$ values across samples. An in-line reference flow cell was immobilized with an unrelated nicotine mAb (**NIC-1 9D9**) at the same level as the ghrelin mAbs. Ghrelin was diluted in running buffer so as to obtain a series of concentrations ranging from 0.2 nM to 4 µM. At least 5 different concentrations of ghrelin were injected into the flow cell for repeated analysis with double references,³⁷ and the interaction between soluble ghrelin and mAb was recorded on a sensorgram. The kinetic data were evaluated via fitting the experimental data with BIAevaluation software (v. 4.1) using an appropriate kinetic model. Kinetic constants, including the association and dissociation equilibrium rate constants (K_a and K_d) and association and dissociation rate constants (k_{on} and k_{off}), were calculated separately for each mAb. All BIAcore kinetic analyses were double-referenced, i.e., with a reference flow cell and blank buffer run.

Epitope mapping by BIAcore

To reveal the steric relationships between antigenic sites on acyl-ghrelin that were potentially recognized by the defined mAbs, a pairwise epitope mapping experiment was performed using surface plasmon resonance (SPR) technology. For this, each defined mAb was immobilized onto a CM5 chip via NHS/EDC amine-coupling, followed by the injection of a saturating concentration (10 μ M) of acyl-ghrelin. Once the surface was saturated, a secondary mAb was injected, and binding activity was observed in real-time via the sensorgram. This procedure was repeated for all mAbs with all possible binary combinations undertaken, and the binding signal for each pair of mAbs was recorded in a reactivity pattern matrix for further analysis.³⁸ All BIAcore epitope mapping analyses were double-referenced to a reference flow cell (with the unrelated anti-nicotine antibody) and blank cell.

Animal Protocols and Antibody Administration

All mouse studies adhered to the *National Institutes of Health Guide for the Care and Use of Laboratory Animals* and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute. Twelve adult male C57BL/6J mice (25.0 – 28.3 g) were purchased from Charles River Laboratories (Frederick, MD) for each of 4 replicate experiments ($n=48$ total). Mice were housed in single cages in a temperature-controlled vivarium (60% humidity, 22°C) with a 12-hour light/12-hour dark cycle (6:30am – 6:30pm) with *ad libitum* access to water and standard pelleted chow diet (LM-485 Diet 7012; Harlan Teklad, Madison, WI) for 2–3 weeks prior to antibody injection. Antibodies were prepared in phosphate buffered saline (pH 7.4) and injected subcutaneously in 130 μ L volumes to obtain final total administered antibody doses of 15 mg/kg (5 mg/kg per mAb for triplet injection, 7.5 mg/kg each for doublets). mAbs were injected five days prior to calorimetric experiments to allow adequate distribution *in vivo*.³⁹

Metabolic and Food Intake

Subjects were singly housed and acclimated (>72 h) to indirect calorimetry chambers where O₂ consumption, CO₂ emission, and heat dissipation were measured using a computer-controlled, open-circuit system (Oxymax System) that was part of an integrated Comprehensive Lab Animal Monitoring System (Columbus Instruments, Columbus, OH). The Plexiglas test chambers (20 $\times$ 10 $\times$ 12.5 cm) had a stainless steel elevated wire floor and were equipped with a sipper tube delivering water and a food tray connected to a balance. Room air was passed through chambers at a flow rate of 0.5 liters/min. Exhaust air from each chamber was sampled at 20 min intervals for 30 sec. Sample air was sequentially passed through O₂ and CO₂ sensors (Columbus Instruments) for determination of O₂ and CO₂ content, from which measures of oxygen consumption (VO₂) and carbon dioxide production (VCO₂) were estimated. Outdoor air reference values were sampled after every four measurements. Gas sensors were regularly calibrated with primary gas standards containing known concentrations of O₂, CO₂, and N₂ (Airgas Puritan Medical, Ontario, CA). Respiratory exchange ratio (RER) was calculated as the ratio of carbon dioxide production (VCO₂) to oxygen consumption (VO₂). Energy expenditure measures (VO₂, VCO₂, and heat formation [(3.815 + 1.232 $\times$ RER) $\times$ VO₂ (in liters)]) were corrected for estimated effective metabolic mass per Kleiber's power function. Data were recorded under ambient room temperature (24–26 °C). During acclimation, powdered chow and water were available *ad libitum*. Subjects were then subjected to a 24 hr fast beginning from the onset of the light cycle, during which water, remained available. At the onset of the next light cycle, mice were allowed to refeed for 6 hr, during which food intake was automatically measured by a computer-monitored scale bearing the food tray (0.1 g precision). Data were graphed using Prism software (GraphPad Software Inc., San Diego, CA). All values were plotted as the mean $\pm$ standard error of the mean (SEM).

Statistical Analysis

Data were analyzed by two-way analysis of covariance (ANOVA), with hapten group as a between-subject factor (e.g., vehicle vs. doublet AB vs. doublet AC vs doublet BC), time as a repeated measure (where applicable), and cohort as a covariate. To assure reproducibility of findings, subjects were run in 4 independent cohorts per experiment (2 ×), balanced for treatment group. Significant omnibus tests ($p < 0.05$) were further interpreted by simple effects analysis and by ANCOVAS comparing individual hapten groups to the vehicle condition. Results are expressed as mean ± SEM. The statistical package used was Systat 12.0 (SPSS, Chicago, IL).

RESULTS

Monoclonal Antibodies Bind With High Specificity to Acyl-ghrelin

Monoclonal antibody affinity to full-length acyl-ghrelin was initially tested by ELISA.²⁶ **JG4 1C4** had the highest affinity to the peptide with an estimated K_d of 6.2 nM. **JG3 8H11** and **JG2 7B4** mAbs had relative affinities estimated by ELISA of 50 nM and 800 nM respectively. Noteworthy was that mAb **JG4** failed to bind *des*-acyl-ghrelin up to 3 μM, whereas the other two mAbs demonstrated binding as potent as 3 nM for *des*-acyl Ghr (BIAcore endpoint analysis, data not shown). A more accurate determination of antibody affinity/specificity was undertaken by BIAcore due to the instrument's ability to monitor real time kinetics as well as its sensitivity to low vs. high affinity antibodies.^{40–42} **JG4**, **JG2**, and **JG3** had relative K_d 's of 77.6 pM, 12.3 nM, and 26.9 nM for acyl-ghrelin, confirming mAb **JG4** to have the highest affinity to the peptide. Kinetic analysis through BIAcore provided kinetic association and dissociation constants (Table 1). **JG4** and **JG2** bind full-length acyl-ghrelin fitting a 1:1 binding with mass transfer model and a 1:1 Langmuir binding model. **JG3** however, has relatively slow k_{on}/k_{off} rates and as such fits a two state reaction model in which a conformational change of the peptide is hypothesized to occur during the association phase.

To examine epitope fidelity, the truncated peptides Ghr 1–5 and Ghr 1–10 were tested. As anticipated, only mAb **JG4** presented binding for these *N*-terminal fragments with relative affinities of 1.01 nM and 136.0 pM respectively. These BIAcore analyses further validate **JG4**'s recognition of the octanoylated serine-3 residue with high specificity to the *N*-terminus of acyl-ghrelin.

Through simple epitope mapping it was determined that **JG4** and **JG2** recognize distinct binding epitopes on ghrelin, whereas **JG3** must recognize a “conformational epitope” that may overlap with the recognition sequence for **JG2** and **JG4**. Specifically, initial binding of **JG3** to ghrelin did not exclude the subsequent binding of **JG2** or **JG4** mAbs to the ghrelin/**JG3** complex. However, initial binding of either **JG2** or **JG4** to ghrelin excluded the subsequent binding of **JG3** to the **JG2**- or **JG4**-ghrelin complex. These data suggest that upon **JG3** binding to ghrelin, a conformational change occurs, perhaps in which the naturally extended secondary structure of ghrelin folds into a more stable loop/supercoil.⁴³ Conversely, the initial binding of **JG2** or **JG4** may prevent the linear ghrelin from folding, which is hypothesized to be crucial for forming a stable complex with **JG3** (see Figure 1).

JG3:JG4 Doublet Uniquely Alters Whole-Body Metabolism in Fasted and Refeeding Mice

Due to the high binding affinity of **JG4 1C4** to acyl-ghrelin, we began calorimetry experiments by injecting mice subcutaneously with only mAb **JG4** at a dose of 15 mg/kg. Initial calorimetric and food intake studies demonstrated no significant differences between monoclonal antibody **JG4 1C4** and the nicotine control antibody **NIC-1 9D9** in male C57BL/6J mice for any of the whole-body metabolism measures (heat, VO_2 , VCO_2 , and

respiratory exchange ratio [RER]) at any time point of the fast or refeeding stages (data not shown). **JG4 1C4** also did not alter cumulative food intake after the 24 hr fast at any time point through 6 hr (data not shown). Based on our positive active immunization findings, we were led to ask whether an oligoclonal antibody response might better enable acyl-ghrelin sequestration, as has been observed for other systems.²⁶ Thus, monoclonal antibodies were further examined as doublets **JG2:JG4**, **JG3:JG4**, and **JG2:JG3** at 7.5 mg/kg per antibody.

Main effects of doublet indicated that the ghrelin doublet cocktails elicited effects on energy expenditure (heat; $F(3,30) = 3.570$, $p < 0.025$; VCO_2 ; $F(3, 30) = 4.003$, $p < 0.016$; VO_2 ; $F(3, 30) = 2.431$, $p < 0.085$); and respiratory exchange ratio (RER); $F(3, 30) = 3.642$, $p < 0.024$). Pairwise comparisons showed that subjects injected with doublet **JG3:JG4** demonstrated significantly higher heat dissipation ($\text{kcal/hr} \cdot \text{kg}^{0.75}$) (heat; $F(1,14) = 8.565$, $p < 0.011$), with increased CO_2 emission (VCO_2 ; $F(1,14) = 6.898$, $p < 0.020$) and O_2 consumption (VO_2 ; $F(1,14) = 4.511$, $p < 0.052$), as well as greater respiratory exchange ratio (RER); $F(1,14) = 7.511$, $p < 0.016$) during the first 14 hr of the fast as compared to nicotine control mAb subjects (Figure 2). In contrast, mice treated with **JG2:JG4** showed a main effect only on heat dissipation (heat; $F(1,14) = 6.756$, $p < 0.021$), however, pairwise analysis of individual time bins showed no significance. The **JG2:JG3** doublet did not differ from control mAb-treated mice within any time-bin of the fast on the metabolic measures.

During the refeeding stage, mice injected with doublet **JG3:JG4** demonstrated significant increase in heat dissipation during hour two as well as increased CO_2 emission during hours two and six (Figure 3, heat; $F(1, 14) = 8.869$, $p < 0.010$; VCO_2 ; $F(1, 14) = 6.601$, $p < 0.022$), suggesting the continuation of relative increases in energy expenditure even during energy repletion. During refeeding, a trend was observed in VO_2 consumption across groups (VO_2 ; $F(3, 30) = 2.498$, $p < 0.079$), whereas, respiratory exchange ratio no longer differed reliably between groups (RER; $F(3, 30) = 1.830$, $p < 0.163$). Caloric intake across the 6-hr period was not significantly different between any of the doublet groups vs. the nicotine control group (Figure 4; intake; $F(3, 29) = 0.387$, $p < 0.763$).

mAb Triplet Cocktail Alters Whole-Body Metabolism and Reduces Caloric Intake in Refeeding Fasted Mice

When mAbs were administered as a “cocktail” combination of all three antibodies (but still at a total dose of 15 mg/kg), significant increases in heat dissipation and O_2 consumption were noted during hours one and two of the refeeding stage (Figure 5; heat hr 1; $F(1,8) = 7.523$, $p < 0.025$; heat hr 2; $F(1, 8) = 6.319$, $p < 0.036$; VO_2 hr 1; $F(1, 8) = 8.189$, $p < 0.021$; VO_2 hr 2; $F(1,8) = 8.136$, $p < 0.021$). The mice administered the cocktail also demonstrated significantly less cumulative caloric intake during the first 6 hrs of the refeeding stage as compared to the nicotine control mice (Figure 6; intake; $F(1, 15) = 1.751$, $p < 0.0001$). Significant reductions in intake were evident as early as 30 min following the return of food to the chambers.

DISCUSSION

With health complications attributable to obesity rising at an alarming rate,⁴⁴ ghrelin systems have been targeted as a potential means to facilitate weight loss. Ghrelin, the only peripheral octanoylated, orexigenic peptide known to date, has been hypothesized to promote meal initiation⁵ and reduce energy expenditure,^{9–11} especially as a feedback response to negative energy balance.⁴⁵ As such, pharmacologic agents that target ghrelin, its endogenous receptor, or its posttranslational octanoylation may be useful not only for understanding the biology of ghrelin, but also for facilitating weight loss by blunting deprivation-induced food intake or by disinhibiting energy expenditure from the “thriftness” response to under-nutrition.⁴⁶

Previously, GHS-R1a-mediated antagonists such as isoxazole carboxamides developed by Abbott have demonstrated modestly potent inhibition of the receptor with an IC₅₀ of 130 nM; however, the compounds suffered from poor pharmacokinetic profiles due to less than 5% oral bioavailability in rats.²³ Ghrelin *O*-acyltransferase inhibitors⁴⁷, such as GO-CoA-Tat developed by Barnett and colleagues, prevented significant weight gain in mice fed a MCT-rich, high fat diet. However, GOAT modulation is a relatively new approach, and only two peptide-based inhibitors have been established to date with minimal *in vivo* modeling.^{48, 49}

Here, rather than using a small molecule or GOAT enzyme inhibitor pharmacological approach, we used immunopharmacotherapy, a strategy we have applied successfully in other fields such as drug abuse and dependence.^{50–52} In the present study, we targeted acyl-ghrelin in mice by generating and administering multiple monoclonal antibodies created against three distinct haptens. All mAbs bound with high specificity to the active octanoylated form of ghrelin *in vitro* with mAb **JG4 1C4** having the highest affinity to the peptide (77.6 pM). **JG4** was procured against a hapten containing only the first ten residues of acyl-ghrelin along with a C-terminal cysteine used for conjugation to the carrier protein KLH. Correspondingly, **JG4** binds with high affinity to the N-terminus of full-length acyl-ghrelin as well as acyl-ghrelin fragments 1–5 and 1–10. In contrast, **JG2** mAb was prepared against a hapten containing the C-terminal ghrelin residues 13–28 and binds both acyl and *des*-acyl forms of ghrelin *in vitro*, presumably at their C-terminus. mAb **JG3** was created against the full-length peptide and, like **JG2**, complexes with both *des*-acyl-ghrelin and acyl-ghrelin. Unlike **JG2**, however, **JG3** appears to recognize internal peptide binding sites, as indicated by kinetic and epitope mapping BIAcore analysis.

Previously, we and others had demonstrated that active immunization targeting the N-terminal portion of ghrelin could reduce weight gain, increase energy expenditure and/or reduce food intake in multiple species.^{26–28} In contrast, a previous study using passive immunization with a monoclonal antibody against ghrelin showed inefficacies in reducing food intake or body weight in mice over a four-week chronic study.³⁰ To reconcile these disparate findings, we hypothesized that a passive oligoclonal “cocktail” of the obtained mAbs, might serve as a “minimal” polyclonal response as elicited by active immunization. That is, we considered a combination of monoclonals might be effective in blunting fasting-induced reductions in energy expenditure and increases in food intake, wherein a singular monoclonal antibody had been ineffective. Indeed, consistent with the findings of Lu and colleagues (2009), we found that passive immunization with a single specific, high-affinity (<100 pM) monoclonal antibody that targeted the ghrelin N-terminus (**JG4**) was ineffective in altering energy expenditure, fuel substrate utilization, or food intake in fasted mice. In contrast, a “doublet” treatment that combined **JG4** with a particular C-terminally directed anti-ghrelin antibody (**JG3**), maintained greater energy expenditure and utilization of carbohydrate as a fuel substrate in fasted mice. Moreover, a “triplet” mAb cocktail combination that included the additional C-terminally directed antibody (**JG2**) that had been comparably ineffective in conjunction with **JG3** or **JG4** alone, not only promoted increased energy expenditure, but also reduced deprivation-induced food intake. The JG3:JG4 complex may have altered secondary structure of the ghrelin peptide, which could significantly reduce positive interaction at the GHSR1a,^{53, 54} due to JG3’s ability to bind ghrelin only in a conformational manner as demonstrated by BIAcore analysis.

Growth hormone secretagogue receptors are expressed not only in the brain, but also along the vagal afferent fibers.^{18, 55} As such, effective anti-ghrelin immunoneutralization may require that antibodies not only prevent BBB passage, but also ligand-receptor interaction at the vagus nerve. If mAbs targeted not only the post-translationally modified serine residue that is key to GHSR1a signaling, but also other potential recognition sites along the peptide that are critical for initially addressing the receptor, then a fully sequestered acyl-ghrelin

might be prevented from forming the secondary structures necessary for lipid membrane interaction and subsequent GHSR1a activation.^{56, 57} Indeed, as is known for NPY and many other peptide-GPCR systems, amphiphilic stretches along the ligand hormone serve to first anchor the peptide onto the lipid bilayer and subsequently permit activation of the membrane bound receptor.^{58, 59} Thus, perhaps the present oligoclonal approach more effectively prevented ultimate signaling at the GPCR, by also interfering with appropriate peptide “recognition”, rather than by relying only on immunoneutralization of “signaling” epitopes.

The mAb doublet **JG3:JG4** bound ghrelin in a manner that increased relative energy expenditure and the relative utilization of carbohydrate as a fuel source in fasted C57BL/6J mice. The mechanism underlying the greater efficacy of the triplet vs. doublet combination to modulate deprivation-induced food intake is uncertain, but perhaps relates to a greater ability of the triplet combination to interfere with ghrelin-signaling at the vagus. That is, perhaps the doublet combination is sufficient to disrupt BBB penetration by ghrelin and consequent hypothalamic GHSR1a stimulation, whereas only the triplet combination was sufficient to abrogate peripheral ghrelin signaling, which is known to contribute to ghrelin induced feeding.¹⁸ Another possible explanation is that perhaps a lower threshold of cumulative GHS-R1a receptor stimulation is required to promote feeding responses as opposed to inhibit energy expenditure. In this view, only the triplet cocktail combination was sufficient to reduce total ghrelin signaling below both thresholds of receptor stimulation.

Several limitations of the present immunoneutralization approach require mentioning. While monoclonal antibodies may be able to sequester acyl-ghrelin in the periphery, binding to CNS derived ghrelin would not be feasible, thus allowing for the evolution of a compensatory mechanism in which central GHS-R1a activation may depend predominantly on ghrelin produced and/or modified in the CNS. A peripheral compensation could also evolve in response to decreasing bioavailable levels of circulating acyl-ghrelin, leading to greater enteric ghrelin synthesis and secretion that potentially could surmount passive immunization or cause unanticipated, adverse local effects. Finally, any potential therapies involving mAbs would require multiple injections over the sustained period of treatment due to estimated half-lives of 6 to 8 days for IgG monoclonal antibodies in mice and 22 to 23 days in humans.⁶⁰

In summary, we have created three monoclonal antibodies against serine-3 octanoylated ghrelin towards understanding the requirements for effective anti-ghrelin immunoneutralization and the effects of ghrelin immunopharmacotherapy on whole body metabolism and food intake in mice *in vivo*. We have concluded that an oligoclonal response is necessary to maintain greater whole body energy expenditure during fasting and subsequent refeeding over a 24-hour period, as well as to reduce overall food intake upon refeeding. These results coincide with data from ourselves and others, whereby active vaccination against acyl-ghrelin decreased feed efficiency, relative adiposity, and body weight gain in three different species. Additional studies will further elucidate the role of immunopharmacotherapy against ghrelin and other metabolic targets in combating obesity through energy homeostasis pathways.

Acknowledgments

This work was supported by the NIH (R21 DK072169), McDonald's Center for Type 2 Diabetes and The Skaggs Institute for Chemical Biology. The authors thank Sarah Parylak and Diane Kubitz for technical assistance with calorimetry experiments and ELISA studies.

References

1. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths attributable to obesity in the United States. *JAMA*. 1999; 282:1530–1538. [PubMed: 10546692]
2. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. *JAMA*. 2007; 298:2028–2037. [PubMed: 17986696]
3. Schloegl H, Percik R, Horstmann A, Villringer A, Stumvoll M. Peptide hormones regulating appetite-focus on neuroimaging studies in humans. *Diabetes Metab. Res. Rev.* 2011; 27:104–112. [PubMed: 21294236]
4. Kojima M, Kangawa K. Ghrelin: structure and function. *Physiol. Rev.* 2005; 85:495–522. [PubMed: 15788704]
5. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. *N. Engl. J. Med.* 2002; 346:1623–1630. [PubMed: 12023994]
6. Bizzarri C, Rigamonti AE, Luce A, Cappa M, Cella SG, Berini J, Sartorio A, Muller EE, Salvatoni A. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children. *Eur. J. Endocrinol.* 2010; 162:499–505. [PubMed: 20019130]
7. Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, Basdevant A, Weigle DS. Elevated plasma ghrelin levels in Prader Willi syndrome. *Nat. Med.* 2002; 8:643–644. [PubMed: 12091883]
8. Qi X, Reed JT, Wang G, Han S, Englander EW, Greeley GH Jr. Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2008; 295:R429–R435. [PubMed: 18495830]
9. Yasuda T, Masaki T, Kakuma T, Yoshimatsu H. Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. *Neurosci. Lett.* 2003; 349:75–78. [PubMed: 12946556]
10. De Smet B, Depoortere I, Moechars D, Swennen Q, Moreaux B, Cryns K, Tack J, Buyse J, Coulie B, Peeters TL. Energy homeostasis and gastric emptying in ghrelin knockout mice. *J. Pharmacol. Exp. Ther.* 2006; 316:431–439. [PubMed: 16203827]
11. Wortley KE, del Rincon JP, Murray JD, Garcia K, Iida K, Thorner MO, Sleeman MW. Absence of ghrelin protects against early-onset obesity. *J. Clin. Invest.* 2005; 115:3573–3578. [PubMed: 16322795]
12. Zhang W, Majumder A, Wu X, Mulholland MW. Regulation of food intake and body weight by recombinant proghrelin. *Am. J. Physiol. Endocrinol. Metab.* 2009; 297:E1269–E1275. [PubMed: 19789292]
13. Bennett KA, Langmead CJ, Wise A, Milligan G. Growth hormone secretagogues and growth hormone releasing peptides act as orthosteric super-agonists but not allosteric regulators for activation of the G protein $G_{\alpha(ol)}$ by the Ghrelin receptor. *Mol. Pharmacol.* 2009; 76:802–811. [PubMed: 19625579]
14. Chen HY, Trumbauer ME, Chen AS, Weingarh DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, Qian S. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. *Endocrinology*. 2004; 145:2607–2612. [PubMed: 14962995]
15. Varela L, Vazquez MJ, Cordido F, Nogueiras R, Vidal-Puig A, Dieguez C, Lopez M. Ghrelin and lipid metabolism: key partners in energy balance. *J. Mol. Endocrinol.* 2011; 46:R43–R63. [PubMed: 21169422]
16. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. *Endocrinology*. 2000; 141:4255–4261. [PubMed: 11089560]
17. Faulconbridge LF, Cummings DE, Kaplan JM, Grill HJ. Hyperphagic effects of brainstem ghrelin administration. *Diabetes*. 2003; 52:2260–2265. [PubMed: 12941764]

18. Date Y, Murakami N, Toshinai K, Matsukura S, Nijima A, Matsuo H, Kangawa K, Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. *Gastroenterology*. 2002; 123:1120–1128. [PubMed: 12360474]
19. Date Y, Shimbara T, Koda S, Toshinai K, Ida T, Murakami N, Miyazato M, Kokame K, Ishizuka Y, Ishida Y, Kageyama H, Shioda S, Kangawa K, Nakazato M. Peripheral ghrelin transmits orexigenic signals through the noradrenergic pathway from the hindbrain to the hypothalamus. *Cell Metab*. 2006; 4:323–331. [PubMed: 17011505]
20. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kangawa K, Nakazato M. Ghrelin-induced food intake is mediated via the orexin pathway. *Endocrinology*. 2003; 144:1506–1512. [PubMed: 12639935]
21. Gahete MD, Cordoba-Chacon J, Salvatori R, Castano JP, Kineman RD, Luque RM. Metabolic regulation of ghrelin O-acyl transferase (GOAT) expression in the mouse hypothalamus, pituitary, and stomach. *Mol. Cell. Endocrinol*. 2010; 317:154–160. [PubMed: 20035826]
22. Esler WP, Rudolph J, Claus TH, Tang W, Barucci N, Brown SE, Bullock W, Daly M, Decarr L, Li Y, Milardo L, Molstad D, Zhu J, Gardell SJ, Livingston JN, Sweet LJ. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. *Endocrinology*. 2007; 148:5175–5185. [PubMed: 17656463]
23. Moulin A, Ryan J, Martinez J, Fehrentz JA. Recent developments in ghrelin receptor ligands. *ChemMedChem*. 2007; 2:1242–1259. [PubMed: 17520591]
24. Becskei C, Bilik KU, Klusmann S, Jarosch F, Lutz TA, Riediger T. The anti-ghrelin Spiegelmer NOX-B11-3 blocks ghrelin-but not fasting-induced neuronal activation in the hypothalamic arcuate nucleus. *J. Neuroendocrinol*. 2008; 20:85–92. [PubMed: 18081556]
25. Helmling S, Maasch C, Eulberg D, Buchner K, Schroder W, Lange C, Vonhoff S, Wlotzka B, Tschop MH, Rosewicz S, Klusmann S. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. *Proc. Natl. Acad. Sci., U. S. A.* 2004; 101:13174–13179. [PubMed: 15329412]
26. Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM, Janda KD. Vaccination against weight gain. *Proc. Natl. Acad. Sci., U. S. A.* 2006; 103:13226–13231. [PubMed: 16891413]
27. Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. *Domest. Anim. Endocrinol*. 2007; 33:176–189. [PubMed: 16793235]
28. Mayorov, AV.; Janda, KD. Ghrelin Mimetic Polypeptide Hapten Immunoconjugates Having Improved Solubility and Immunogenicity and Methods Of Use Thereof. US Application Serial No. 61/462,912. 2011.
29. Mayorov AV, Amara N, Chang JY, Moss JA, Hixon MS, Ruiz DI, Meijler MM, Zorrilla EP, Janda KD. Catalytic antibody degradation of ghrelin increases whole-body metabolic rate and reduces refeeding in fasting mice. *Proc. Natl. Acad. Sci., U. S. A.* 2008; 105:17487–17492. [PubMed: 18981425]
30. Lu SC, Xu J, Chinookoswong N, Liu S, Stevenson S, Gegg C, Brankow D, Lindberg R, Veniant M, Gu W. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. *Mol. Pharmacol*. 2009; 75:901–907. [PubMed: 19129426]
31. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. *Mol. Cell. Biol*. 2003; 23:7973–7981. [PubMed: 14585959]
32. Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M, Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ, Sleeman MW. Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. *Proc. Natl. Acad. Sci., U. S. A.* 2004; 101:8227–8232. [PubMed: 15148384]
33. Cheng LW, Stanker LH, Henderson TD 2nd, Lou J, Marks JD. Antibody protection against botulinum neurotoxin intoxication in mice. *Infect. Immun*. 2009; 77:4305–4313. [PubMed: 19651864]
34. Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant

- oligoclonal antibody. *Proc. Natl. Acad. Sci., U. S. A.* 2002; 99:11346–11350. [PubMed: 12177434]
35. Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. *Infect. Immun.* 1984; 45:604–609. [PubMed: 6205994]
 36. Zwick MB, Wang M, Poignard P, Stiegler G, Kattinger H, Burton DR, Parren PW. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. *J. Virol.* 2001; 75:12198–12208. [PubMed: 11711611]
 37. Zhou B, Pellett S, Tepp WH, Zhou H, Johnson EA, Janda KD. Delineating the susceptibility of botulinum neurotoxins to denaturation through thermal effects. *FEBS Lett.* 2008; 582:1526–1531. [PubMed: 18396167]
 38. Zhou B, Carney C, Janda KD. Selection and characterization of human antibodies neutralizing *Bacillus anthracis* toxin. *Bioorg. Med. Chem.* 2008; 16:1903–1913. [PubMed: 18023190]
 39. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. *Clin. Pharmacol. Ther.* 2008; 84:548–558. [PubMed: 18784655]
 40. Van Regenmortel MH. Improving the quality of BIACORE-based affinity measurements. *Dev. Biol.* 2003; 112:141–151.
 41. Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, Swanson SJ, Mullenix MC. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. *J. Immunol.* 2007; 178:7467–7472. [PubMed: 17513798]
 42. Liang M, Klakamp SL, Funelas C, Lu H, Lam B, Herl C, Umble A, Drake AW, Pak M, Ageyeva N, Pasumarthi R, Roskos LK. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. *Assay Drug Dev. Technol.* 2007; 5:655–662. [PubMed: 17939757]
 43. Kukol A. The structure of ghrelin. *Vitam. Horm.* 2008; 77:1–12. [PubMed: 17983850]
 44. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. *N. Engl. J. Med.* 1999; 341:1097–1105. [PubMed: 10511607]
 45. Lomenick JP, Clasey JL, Anderson JW. Meal-related changes in ghrelin, peptide YY, appetite in normal weight and overweight children. *Obesity.* 2008; 16:547–552. [PubMed: 18239577]
 46. Dulloo AG, Girardier L. 24 hour energy expenditure several months after weight loss in the underfed rat: evidence for a chronic increase in whole-body metabolic efficiency. *Int. J. Obes. Relat. Metab. Disord.* 1993; 17:115–123. [PubMed: 8384165]
 47. Garner AL, Janda KD. A small molecule antagonist of ghrelin O-acyltransferase (GOAT). *Chem. Commun.* 2011; 47:7512–7514.
 48. Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard V, Lin YY, Bowers EM, Mukherjee C, Song WJ, Longo PA, Leahy DJ, Hussain MA, Tschop MH, Boeke JD, Cole PA. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. *Science.* 2010; 330:1689–1692. [PubMed: 21097901]
 49. Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides. *Proc. Natl. Acad. Sci., U. S. A.* 2008; 105:10750–10755. [PubMed: 18669668]
 50. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active immunization. *Nature.* 1995; 378:727–730. [PubMed: 7501020]
 51. Moreno AY, Janda KD. Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. *Pharmacol. Biochem. Behav.* 2009; 92:199–205. [PubMed: 19350728]
 52. Treweek JB, Roberts AJ, Janda KD. Superadditive effects of ethanol and flunitrazepam: implications of using immunopharmacotherapy as a therapeutic. *Mol. Pharm.* 2010; 7:2056–2068. [PubMed: 20849117]
 53. Morozumi N, Hanada T, Habara H, Yamaki A, Furuya M, Nakatsuka T, Inomata N, Minamitake Y, Ohsuye K, Kangawa K. The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats. *Peptides.* 2011; 32:1001–1007. [PubMed: 21291937]
 54. Staes E, Absil PA, Lins L, Brasseur R, Deleu M, Lecouturier N, Fievez V, des-Rieux A, Mingeot-Leclercq MP, Raussens V, Preat V. Acylated and unacylated ghrelin binding to membranes and to

- ghrelin receptor: towards a better understanding of the underlying mechanisms. *Biochim. Biophys. Acta*. 2010; 1798:2102–2113. [PubMed: 20637180]
55. Cowley MA, Grove KL. Ghrelin--satisfying a hunger for the mechanism. *Endocrinology*. 2004; 145:2604–2606. [PubMed: 15140838]
56. Beevers AJ, Kukol A. Conformational flexibility of the peptide hormone ghrelin in solution and lipid membrane bound: a molecular dynamics study. *J. Biomol. Struct. Dyn.* 2006; 23:357–364. [PubMed: 16363872]
57. Silva Elipe MV, Bednarek MA, Gao YD. ¹H NMR structural analysis of human ghrelin and its six truncated analogs. *Biopolymers*. 2001; 59:489–501. [PubMed: 11745115]
58. Bader R, Zerbe O. Are hormones from the neuropeptide Y family recognized by their receptors from the membrane-bound state? *ChemBioChem*. 2005; 6:1520–1534. [PubMed: 16038001]
59. Kaiser ET, Kezdy FJ. Amphiphilic secondary structure: design of peptide hormones. *Science*. 1984; 223:249–255. [PubMed: 6322295]
60. Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanesian L, Choi EY, Shaffer DJ, Eden PA, Anderson CL. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. *J. Immunol*. 2003; 170:3528–3533. [PubMed: 12646614]

Fig. 1.

Shown is the secondary structure of full-length acyl-ghrelin with potential binding sites of mABs **JG2**, **JG3**, and **JG4**, inferred from BIAcore analysis, highlighted as oval regions. mAB **JG4** recognizes the *N*-terminus of ghrelin, specifically the acylated side chain found on serine-3. mAB **JG3** recognizes an internal binding site on ghrelin, possibly at the loop structure found from residues serine-18 – lysine-20, and mAB **JG2** recognizes the *C*-terminus of ghrelin. *Structure shown modified from PDB 1P7X.*

Fig. 2.

Shown are the rate of energy expenditure (heat, Top Left), respiratory exchange ratio (RER, Top Right), the rates of carbon dioxide production (VCO₂, Bottom Left) and oxygen consumption (VO₂, Bottom Right) in food deprived, antibody-treated, adult male C57BL/6J mice as recorded in open-circuit indirect calorimetry chambers. Data are expressed in 2-hr bins as $M \pm SEM$ during the first 16 hrs of fasting beginning at light onset. Mice received subcutaneous administration (15 mg/kg total dose) of ghrelin mAbs in doublets • JG2:JG4, -■ JG3:JG4, and ▲ JG2:JG3 ($n=6$) or a ▼ nicotine control Ab ($n=6$, NIC-1 9D9) 4 days prior to data collection; *, $p < 0.05$ vs. control Ab-treated mice. Dark onset begins at hrs 13–14 of the fasting stage.

Fig. 3.

Shown are the rate of energy expenditure (heat, Top Left), respiratory exchange ratio (RER, Top Right), the rates of carbon dioxide production (VCO₂, Bottom Left) and oxygen consumption (VO₂, Bottom Right) in antibody-treated, adult male C57BL/6J mice refeeding after a 24-hr fast as recorded in open-circuit indirect calorimetry chambers. Data are expressed in 1-hr bins as $M \pm SEM$ during the first 6 hrs of refeeding beginning at light onset. Mice received subcutaneous administration (15 mg/kg total dose) of ghrelin mAbs in doublets ● JG2:JG4, ■ JG3:JG4, and ▲ JG2:JG3 ($n=6$) or a ▼ nicotine control Ab ($n=6$, NIC-1 9D9) 5 days prior to data collection; *, $p < 0.05$, **, $p < 0.01$ vs. control Ab-treated mice.

Fig. 4. Food intake in 24-hr food-deprived, antibody-treated adult male C57BL/6J mice as recorded in open-circuit indirect calorimetry chambers. Data are expressed in 30 min bins as $M \pm$ SEM during the first 6 hrs of refeeding beginning at light onset. Mice received subcutaneous administration (15 mg/kg total dose) of ghrelin mAbs in doublets • **JG2:JG4**, ■ **JG3:JG4**, and ▲ **JG2:JG3** ($n=6$) or a ▼ nicotine control Ab ($n=6$, **NIC-1 9D9**) 5 days prior to data collection.

Fig. 5.

Shown are the rate of energy expenditure (heat, Top Left), respiratory exchange ratio (RER, Top Right), the rates of carbon dioxide production (VCO₂, Bottom Left) and oxygen consumption (VO₂, Bottom Right) in antibody-treated, adult male C57BL/6J mice as recorded in open-circuit indirect calorimetry chambers. Data are expressed in 1-hr bins as $M \pm \text{SEM}$ during the last hr of the fasting stage ("Unfed") and the first 6 hrs of refeeding beginning at light onset. Mice received subcutaneous administration (15mg/kg total dose) of ghrelin mAbs in triplet ● ghr mAbs **JG2**, **JG3**, & **JG4** ($n=6$) or a ■- nicotine control Ab ($n=6$, **NIC-1 9D9**) 5 days prior to data collection; *, $p < 0.05$ vs. control Ab-treated mice.

Fig. 6.

Food intake in 24-hr food-deprived, antibody-treated adult male C57BL/6J mice as recorded in open-circuit indirect calorimetry chambers. Data are expressed in 30 min bins as $M \pm$ SEM during the first 6 hrs of refeeding beginning at light onset. Mice received subcutaneous administration (15 mg/kg total dose) of ghrelin mAbs in triplet • ghr mAbs **JG2**, **JG3**, & **JG4** ($n=6$) or a -■- nicotine control Ab ($n=6$, **NIC-1 9D9**) 5 days prior to data collection; ***, $p < 0.0001$ vs. control Ab-treated mice.

Table 1

Kinetic analysis of mAbs against acyl-ghrelin and truncated ghrelin peptides by BIAcore

mAb	Hybridoma	Isotype	Full length acyl-Ghr			Ghr 1-5			Ghr 1-10		
			k_{on}	k_{off}	K_d	k_{on}	k_{off}	K_d	k_{on}	k_{off}	K_d
JG2	7B4	$\kappa\gamma 3$	$9.78e^5$	$1.20e^{-2}$	$1.23e^{-8}$	* <i>n.d.</i>	* <i>n.d.</i>	$>5.00\ e^{-5}$	* <i>n.d.</i>	* <i>n.d.</i>	$>5.00\ e^{-5}$
JG3	8H11	$\kappa\gamma 2a$	$9.92e^3$	$2.67e^{-4}$	$2.69e^{-8}$	* <i>n.d.</i>	* <i>n.d.</i>	$>5.00\ e^{-5}$	* <i>n.d.</i>	* <i>n.d.</i>	$>5.00\ e^{-5}$
JG4	1C4	$\kappa\gamma 2a$	$1.02e^7$	$7.92e^{-4}$	$7.76e^{-11}$	$5.43e^6$	$5.46e^{-3}$	$1.01e^{-9}$	$4.90e^6$	$6.67e^{-4}$	$1.36e^{-10}$

* Values not determined due to affinities greater than 50 μM . k_{on} rates represented as (1/M-sec). k_{off} rates represented as (1/sec). K_d values represented in M.